In vitro DDI studies detailed in clinical pharmacology and biopharmaceutics reviews were not included for exenatide and dulaglutide, but were included for liraglutide, semaglutide, and tirzepatide (Table 3)
in the lungs, they alleviate acute respiratory distress syndrome (ARDS) by reducing cytokine production, stimulating surfactant secretion, and preserving alveolar-capillary barrier
Determining the correct dosage, method of administration, and length of each treatment was a steep learning curve
With the disruption of dopaminergic signaling as the main culprit of motor symptoms within PD, pharmacological interventions primarily aim to restore dopamine levels, enhance its action, or modulate related pathways to alleviate motor symptoms
A deficiency in any one of these compounds creates fatigue at a fundamental level that oral supplementation addresses only gradually